Omeros Corporation

Lumithera, Inc.

University of Leicester

Rayner Intraocular Lenses Limited

Rayner Surgical Limited

Rayner Surgical Group Limited

Macula Bidco Limited

Clark E Tedford

James Brian Parent

Thomas Dudler

Gregory A Demopulos

Anita Kavlie

Wayne Richard Gombotz

Sergej Kiprijanov

Urs Beat Hagemann

Herald Reiersen

Hans-Wilhelm Schwaeble

Scott Bradley

Scott Delapp

Hui-rong Shen

Wayne R Gombotz

Cordula M Stover

Thomas A Dudler

Urs B Hagemann

Hui-Rong Shen

Teizo Fujita

Cordula Margaret Stover

Teiz0 Fujita

Methods for treating ocular diseases such as dry age-related macular degeneration include administering non-invasive photobiomodulation light therapy in the context of a prior PBM treatment, on the basis of a subject response to prior PBM treatment, on the basis of a patient pre-treatment characteristic, and combinations thereof. In some embodiments, methods comprise administering PBM therapy to subjects who have received PBM about four to six months prior to the present administering. In some embodiments, methods comprise administering PBM therapy to subjects in early stages of dry age-related macular degeneration.

Methods for treating ocular disease

Provided are multi-wavelength phototherapy devices, systems and methods for the treatment of a disorder or disease, including multi-wavelength low level light therapy ('PBM'), in particular to multi-wavelength PBM and other phototherapy systems and methods for improving functionality in and/or restoring functionality to a cell and/or tissue through the coordinated and targeted delivery to the cell or tissue of two or more doses of light having distinct wavelengths, wherein the two or more doses of light, when delivered in a coordinated fashion, can stimulate the activity of two or more light sensitive factors that, when activated, provide and/or enhance a desired target cell functionality. Ophthalmic phototherapy devices, systems, and treatment methods to expose an eye to selected multi-wavelengths of light to promote the healing of damaged or diseased eye tissue. The devices include a housing having an interior; an eyepiece disposed on the housing and configured and arranged for placement of an eye of the patient adjacent the eyepiece; a first light source producing a first light beam having a first therapeutic wavelength and disposed within the housing; a second light source producing a second light beam having a second therapeutic wavelength and disposed within the housing, where the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm.

Multi-wavelength phototherapy devices, systems, and methods for the non-invasive treatment of damaged or diseased tissue

The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.

Stable preservative-free mydriatic and anti-inflammatory solutions for injection

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Methods for treating conditions associated with MASP-2 dependent complement activation

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Compositions for inhibiting MASP-2 dependent complement activation

Multi-wavelength phototherapy systems and methods for the treatment of damaged or diseased tissue

An ophthalmic phototherapy device and associated treatment methods to expose an eye to selected multi-wavelengths of light to promote the healing of damaged or diseased eye tissue. The device includes a housing having an interior; an eyepiece disposed on the housing and configured and arranged for placement of an eye of the patient adjacent the eyepiece; a first light source producing a first light beam having a first therapeutic wavelength and disposed within the housing; a second light source producing a second light beam having a second therapeutic wavelength and disposed within the housing, where the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm.

Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatments

Growing community of inventors

Poulsbo, WA, United States of America

Clark E Tedford